Marker Could ID Lung Cancer Patients Likely to Benefit From EGFR Inhibition
Patients with stage IV squamous cell lung cancer positive for an EGFR gene copy number biomarker saw a survival benefit when adding cetuximab to chemotherapy.
Most Young Lung Cancers Patients Have Targetable Genes
Seventy-five percent of patients diagnosed with metastatic adenocarcinoma of the lung before age 40 have an actionable mutation, according to preliminary results from the Genomics of Young Lung Cancer Study.
Lung Cancer Incidence Increasing Among Nonsmokers
The incidence of NSCLC among self-reported never-smokers appears to be increasing, according to authors of two retrospective studies presented at the 2015 World Conference on Lung Cancer.
Revised TNM Classification of Lung Cancer to Offer More Precise Staging
The newly revised 8th edition of the tumor, node, and metastasis (TNM) classification of lung cancer will improve the precision of staging and provide physicians with new data with which to treat patients.
IMMU-132 Encouraging in Previously Treated Metastatic Lung Cancer
The investigational agent IMMU-32 is well-tolerated in patients with previously-treated metastatic lung cancer, and interim survival data are “encouraging.”
Bevacizumab Improved Survival in Mesothelioma
Adding the angiogenesis inhibitor bevacizumab to standard cisplatin/pemetrexed chemotherapy prolonged survival by more than 2 months among patients with malignant pleural mesothelioma.
Adjuvant Chemo-Immunotherapy May Improve NSCLC Survival
Postsurgical chemo-immunotherapy offers improved survival rates for patients with NSCLC, compared to adjuvant chemotherapy alone, according to a small phase III study.
First-line Nivolumab/Ipilimumab Demonstrate ‘Deep,’ ‘Durable’ Activity
Treatment with nivolumab and ipilimumab is clinically active and has a manageable safety profile for chemotherapy-naive patients diagnosed with advanced NSCLC.
Early Recognition of Immunotherapy Toxicities Essential
Oncology teams need to spot emerging immune-related adverse events associated with immunotherapies early in order to avoid treatment discontinuation.